Drug: Cimzia (certolizumab pegol)

Manufacturer: UCB, Inc.

Route of Administration: Subcutaneous

Site of Care: Outpatient

Approved Indication:

• reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
• treatment of adults with moderately to severely active rheumatoid arthritis/strong>
• treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
• treatment of adult patients with active psoriatic arthritis
• treatment of adults with active ankylosing spondylitis
• treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
• treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy